KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
Novo Nordisk’s $1.3 Billion Acquisition of Ocedurenone
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...